Document is current

Article History

Received: 3 March 2024

Revised: 18 December 2024

Accepted: 20 February 2025

First Online: 1 March 2025

Competing interests

: AS received travel support from Merck. FE received honoraria for lectures and travel grants from Dr. Sennewald Medizintechnik GmbH and honoraria for consultation and advisory board participation from Servier Austria. FF is the Editor of Oncoplastic Surgery Part I and II SPRINGER. Advisory Role, Travel support, and scientific support Novartis, Roche, Astra Zeneca, Pfizer, and Lilly. GP received grants and honoraria from Pfizer, Amgen, Astra Zeneca, Novartis, Roche, Daichii, Seagen, MSD, and Lilly. GW received restricted travel grants from NX Development Corp. MP has received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Servier. ASB has research support from Daiichi Sankyo, Roche, and honoraria for lectures, consultation, or advisory board participation from Roche Bristol-Meyers Squibb, Merck, Daiichi Sankyo as well as travel support from Roche, Amgen, and AbbVie. All other authors claimed no conflict of interest.

: All methods of this study were performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki). The study, along with the associated data collection and analysis, received approval from the Ethics Committee of the Medical University of Vienna (Ethics Number 1692/2022). Data collected were fully anonymised.

: Due to the retrospective design of the study, the ethics board waived the informed consent of individual patients.